Quince Therapeutics (now IRulya) agrees to $11.5 million private placement

Quince Therapeutics, Inc. (Nasdaq: QNCX) agreed on June 12, 2025 to sell common stock, pre-funded warrants and common warrants in a private placement for aggregate gross proceeds of approximately $11.5 million. The company disclosed the deal in a Form 8-K dated June 13, 2025. The filing identifies the buyers only as "certain institutional investors" and "certain members of the Company's management." It refers to "placement agent fees and other expenses payable by the Company" but does not name a placement agent, and it does not name the counsel on either side.

What investors receive

Quince agreed to issue 6,671,928 shares of common stock and pre-funded warrants to buy up to 2,000,000 shares. Each share and each pre-funded warrant comes with one common warrant, for up to 8,671,928 shares in total. The combined purchase price is $1.325 for each share and accompanying common warrant, and $1.324 for each pre-funded warrant and accompanying common warrant. The filing says the $1.325 price includes $0.125 per common warrant, in line with Nasdaq rules on how such bundled prices are set.

A pre-funded warrant lets a buyer pay almost the full price up front and exercise at $0.001 per share later. Holders cannot exercise any warrant to the extent that they would own more than 4.99% of the outstanding common stock immediately afterward, or 9.99% if the holder elects that cap at issuance.

Each common warrant can be exercised for one share at $1.20 and expires five years after its issuance. The holder may instead take a cashless exercise in lieu of paying cash. Cash exercise in full of all common warrants could bring in up to approximately $10.4 million more. That money is not in hand. It arrives only if holders choose to pay $1.20 a share, and the filing does not promise that they will.

Insider purchases

Three executives bought in the offering. Dirk Thye, the company's Chief Executive Officer, Chief Medical Officer and a member of the board, bought shares and common warrants for $200,000. Brendan Hannah, Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, paid $50,000. Charles Ryan, the President, paid $10,000. Those purchases are small next to the $11.5 million gross figure.

Registration and the exemption used

Under a registration rights agreement dated June 12, 2025, Quince agreed to file a resale registration statement covering the shares, the pre-funded warrant shares and the common warrant shares no later than the 120th day after the agreement. The securities were sold under Section 4(a)(2) of the Securities Act and Regulation D and have not been registered.

The business behind the raise

The annual report describes Quince as a late-stage biotechnology company. Its lead asset, eDSP, uses its AIDE platform to encapsulate DSP, a corticosteroid, in a patient's own red blood cells. It is in the pivotal Phase 3 NEAT trial in A-T, a rare pediatric neurodegenerative disease. The trial began enrolling in June 2024, and as of March 24, 2025 it had 61 participants. The company lists completing enrollment in the second quarter of 2025 and reporting topline results in the fourth quarter of 2025 as milestones, with an NDA and a European application in 2026 only if the results are positive. The FDA granted Fast Track designation in June 2024. The company estimates about 4,600 diagnosed A-T patients in the United States and calls the global market a $1+ billion peak opportunity, on its own internal estimates.

A second program, in DMD, is to advance with capital-efficient studies and depends on grant or opportunistic funding. The company says more expansion beyond A-T and DMD is subject to additional funding.

What the filing does not say

The 8-K does not state Quince's cash balance, its cash burn or how long the company can fund operations. It does not say how the company will use the net proceeds. The warrants could add up to 8,671,928 shares to the outstanding count, on top of the 6,671,928 common shares and 2,000,000 pre-funded shares sold now. The $1.20 exercise price sits below the $1.325 combined price investors pay, so the warrants have value only if the stock trades above $1.20.

Report an error

Companies in this story

IRLAIRulya Therapeutics Inc.NASDAQ · United StatesOpen the starter deskQNCXIRulya Therapeutics Inc.NASDAQ · Not recordedOpen the starter desk